Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Rilzabrutinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 13,206Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sanofi's Wayrilz Recommended For EU Approval For thrombocytopenia
    Sanofi's Wayrilz Recommended For EU Approval For thrombocytopenia

    17 Oct 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-17-11-05-00-3168539

    PRESS RELEASE
    17 Oct 2025
    Share Share
    Onco360® Chosen as National Pharmacy Partner for Wayrilz
    Onco360® Chosen as National Pharmacy Partner for Wayrilz

    08 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/08/3146482/0/en/Onco360-Has-Been-Selected-as-a-National-Specialty-Pharmacy-Partner-for-Wayrilz-rilzabrutinib.html

    GLOBENEWSWIRE
    08 Sep 2025
    Share Share
    Sanofi's Wayrilz FDA Approved as First BTK Inhibitor for Immune
    Sanofi's Wayrilz FDA Approved as First BTK Inhibitor for Immune

    29 Aug 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-08-29-21-50-18-3141825

    PRESS RELEASE
    29 Aug 2025
    Share Share
    Genzyme's Wayrilz Receives Approval in US
    Genzyme's Wayrilz Receives Approval in US

    29 Aug 2025

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219685

    FDA
    29 Aug 2025
    Share Share
    Sanofi's Rilzabrutinib Granted EU Orphan Designation
    Sanofi's Rilzabrutinib Granted EU Orphan Designation

    14 Aug 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-08-14-05-00-00-3133146

    PRESS RELEASE
    14 Aug 2025
    Share Share
    Rilzabrutinib Grants Orphan Designation for Sickle Cell Disease
    Rilzabrutinib Grants Orphan Designation for Sickle Cell Disease

    03 Jun 2025

    // PRESS RELEASE

    https://www.sanofi.com/en/media-room/press-releases/2025/2025-06-03-05-00-00-3092429

    PRESS RELEASE
    03 Jun 2025
    Share Share